The ways and means of fragment-based drug design

Pharmacology and Therapeutics

Volumn 167, Issue , 2016, Pages 28-37

  Doak, Bradley C ^a   Norton, Raymond S ^a   Scanlon, Martin J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Medicinal chemistry; Protein; Screening; Structure based drug design

Indexed keywords

ONALESPIB; VEMURAFENIB; VENETOCLAX; DRUG; LIGAND; PROTEIN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHEMICAL REACTION; CLICK CHEMISTRY; COMBINATORIAL CHEMISTRY; CONCENTRATION AT STEADY-STATE; DISSOCIATION CONSTANT; DISSOCIATION RATE CONSTANT; DRUG DESIGN; DRUG PROTEIN BINDING; FRAGMENT BASED DRUG DESIGN; LIGAND BINDING; MOLECULAR LIBRARY; PRIORITY JOURNAL; PROTEIN FUNCTION; THERMODYNAMICS; CHEMISTRY; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY;

DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEINS;

EID: 84993661783     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.07.003     Document Type: Article

References (111)

1. Addie, M., Ballard, P., Buttar, D., Crafter, C., Currie, G., Davies, B.R.,.. Ruston, L., Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 56 (2013), 2059–2073.
2. Allen, C.E., Curran, P.R., Brearley, A.S., Boissel, V., Sviridenko, L., Press, N.J.,.. Armstrong, A., Efficient and facile synthesis of acrylamide libraries for protein-guided tethering. Org Lett 17 (2015), 458–460.
3. Andrews, P.R., Craik, D.J., Martin, J.L., Functional group contributions to drug-receptor interactions. J Med Chem 27 (1984), 1648–1657.
4. Baker, M., Fragment-based lead discovery grows up. Nat Rev Drug Discov 12 (2013), 5–7.
5. Bamborough, P., Brown, M.J., Christopher, J.A., Chung, C.W., Mellor, G.W., Selectivity of kinase inhibitor fragments. J Med Chem 54 (2011), 5131–5143.
6. Banerjee, S., Bartesaghi, A., Merk, A., Rao, P., Bulfer, S.L., Yan, Y.,.. Subramaniam, S., 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. Science 351 (2016), 871–875.
7. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H.,.. Bourne, P.E., The protein data bank. Nucleic Acids Res 28 (2000), 235–242.
8. Bertrand, S.M., Ancellin, N., Beaufils, B., Bingham, R.P., Borthwick, J.A., Boullay, A.B.,.. Young, R.J., The discovery of in vivo active mitochondrial branched-chain aminotransferase (BCATm) inhibitors by hybridizing fragment and HTS hits. J Med Chem 58 (2015), 7140–7163.
9. Bohacek, R.S., McMartin, C., Guida, W.C., The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 16 (1996), 3–50.
10. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., Hirth, P., Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11 (2012), 873–886.
11. Bottcher, J., Jestel, A., Kiefersauer, R., Krapp, S., Nagel, S., Steinbacher, S., Steuber, H., Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology. Methods Enzymol 493 (2011), 61–89.
12. Braisted, A.C., Oslob, J.D., Delano, W.L., Hyde, J., McDowell, R.S., Waal, N.,.. Raimundo, B.C., Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc 125 (2003), 3714–3715.
13. Buck, E., Wells, J.A., Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor. Proc Natl Acad Sci U S A 102 (2005), 2719–2724.
14. Burlingame, M.A., Tom, C.T., Renslo, A.R., Simple one-pot synthesis of disulfide fragments for use in disulfide-exchange screening. ACS Comb Sci 13 (2011), 205–208.
15. Cancilla, M.T., He, M.M., Viswanathan, N., Simmons, R.L., Taylor, M., Fung, A.D.,.. Erlanson, D.A., Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Bioorg Med Chem Lett 18 (2008), 3978–3981.
16. Chen, I.J., Hubbard, R.E., Lessons for fragment library design: Analysis of output from multiple screening campaigns. J Comput Aided Mol Des 23 (2009), 603–620.
17. Chen, W.N., Nitsche, C., Pilla, K.B., Graham, B., Huber, T., Klein, C.D., Otting, G., Sensitive NMR approach for determining the binding mode of tightly binding ligand molecules to protein targets. J Am Chem Soc 138 (2016), 4539–4546.
18. Choong, I.C., Lew, W., Lee, D., Pham, P., Burdett, M.T., Lam, J.W.,.. O'Brien, T., Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J Med Chem 45 (2002), 5005–5022.
19. Chung, S., Parker, J.B., Bianchet, M., Amzel, L.M., Stivers, J.T., Impact of linker strain and flexibility in the design of a fragment-based inhibitor. Nat Chem Biol 5 (2009), 407–413.
20. Congreve, M., Carr, R., Murray, C., Jhoti, H., A ‘rule of three’ for fragment-based lead discovery?. Drug Discov Today 8 (2003), 876–877.
21. Congreve, M.S., Davis, D.J., Devine, L., Granata, C., O'Reilly, M., Wyatt, P.G., Jhoti, H., Detection of ligands from a dynamic combinatorial library by X-ray crystallography. Angew Chem Int Ed Engl 42 (2003), 4479–4482.
22. Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M., Stockman, B., WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability. J Biomol NMR 21 (2001), 349–359.
23. Davis, B.J., Erlanson, D.A., Learning from our mistakes: The ‘unknown knowns’ in fragment screening. Bioorg Med Chem Lett 23 (2013), 2844–2852.
24. Doak, B.C., Morton, C.J., Simpson, J.S., Scanlon, M.J., Design and evaluation of the performance of an NMR screening fragment library. Aust J Chem 66 (2013), 1465–1472.
25. Egger, J., Weckerle, C., Cutting, B., Schwardt, O., Rabbani, S., Lemme, K., Ernst, B., Nanomolar E-selectin antagonists with prolonged half-lives by a fragment-based approach. J Am Chem Soc 135 (2013), 9820–9828.
26. Erlanson, D.A., Hansen, S.K., Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. Curr Opin Chem Biol 8 (2004), 399–406.
27. Erlanson, D.A., Lam, J.W., Wiesmann, C., Luong, T.N., Simmons, R.L., DeLano, W.L.,.. O'Brien, T., In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol 21 (2003), 308–314.
28. Erlanson, D.A., McDowell, R.S., He, M.M., Randal, M., Simmons, R.L., Kung, J.,.. Hansen, S.K., Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. J Am Chem Soc 125 (2003), 5602–5603.
29. Erlanson, D.A., Arndt, J.W., Cancilla, M.T., Cao, K., Elling, R.A., English, N.,.. Sun, L., Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett 21 (2011), 3078–3083.
30. Erlanson, D.A., Braisted, A.C., Raphael, D.R., Randal, M., Stroud, R.M., Gordon, E.M., Wells, J.A., Site-directed ligand discovery. Proc Natl Acad Sci U S A 97 (2000), 9367–9372.
31. Fink, T., Reymond, J.L., Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 47 (2007), 342–353.
32. Gao, J., Wells, J.A., Identification of specific tethered inhibitors for caspase-5. Chem Biol Drug Des 79 (2012), 209–215.
33. Gelin, M., Poncet-Montange, G., Assairi, L., Morellato, L., Huteau, V., Dugue, L.,.. Labesse, G., Screening and in situ synthesis using crystals of a NAD kinase lead to a potent antistaphylococcal compound. Structure 20 (2012), 1107–1117.
34. Guan, J.Y., Keizers, P.H., Liu, W.M., Lohr, F., Skinner, S.P., Heeneman, E.A.,.. Siegal, G., Small-molecule binding sites on proteins established by paramagnetic NMR spectroscopy. J Am Chem Soc 135 (2013), 5859–5868.
35. Hall, R.J., Mortenson, P.N., Murray, C.W., Efficient exploration of chemical space by fragment-based screening. Prog Biophys Mol Biol 116 (2014), 82–91.
36. Hann, M.M., Leach, A.R., Harper, G., Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41 (2001), 856–864.
37. Hardy, J.A., A link means a lot: Disulfide tethering in structure-based drug design. Computational and Structural Approaches to Drug Discovery: Ligand-protein Interactions, 2008, The Royal Society of Chemistry, 319–348 Chapter 17.
38. Herrmann, A., Dynamic combinatorial/covalent chemistry: A tool to read, generate and modulate the bioactivity of compounds and compound mixtures. Chem Soc Rev 43 (2014), 1899–1933.
39. Hochgurtel, M., Biesinger, R., Kroth, H., Piecha, D., Hofmann, M.W., Krause, S.,.. Eliseev, A.V., Ketones as building blocks for dynamic combinatorial libraries: Highly active neuraminidase inhibitors generated via selection pressure of the biological target. J Med Chem 46 (2003), 356–358.
40. Hopkins, A.L., Groom, C.R., Alex, A., Ligand efficiency: A useful metric for lead selection. Drug Discov Today 9 (2004), 430–431.
41. Hopkins, A.L., Keseru, G.M., Leeson, P.D., Rees, D.C., Reynolds, C.H., The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 13 (2014), 105–121.
42. Hu, X., Sun, J., Wang, H.G., Manetsch, R., Bcl-XL-templated assembly of its own protein–protein interaction modulator from fragments decorated with thio acids and sulfonyl azides. J Am Chem Soc 130 (2008), 13820–13821.
43. Huc, I., Lehn, J.M., Virtual combinatorial libraries: Dynamic generation of molecular and supramolecular diversity by self-assembly. Proc Natl Acad Sci U S A 94 (1997), 2106–2110.
44. Ichihara, O., Barker, J., Law, R.J., Whittaker, M., Compound design by fragment-linking. Mol Inf 30 (2011), 298–306.
45. Jencks, W.P., On the attribution and additivity of binding energies. Proc Natl Acad Sci U S A 78 (1981), 4046–4050.
46. John, M., Pintacuda, G., Park, A.Y., Dixon, N.E., Otting, G., Structure determination of protein–ligand complexes by transferred paramagnetic shifts. J Am Chem Soc 128 (2006), 12910–12916.
47. Kathman, S.G., Xu, Z., Statsyuk, A.V., A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases. J Med Chem 57 (2014), 4969–4974.
48. Keseru, G.M., Erlanson, D.A., Ferenczy, G.G., Hann, M.M., Murray, C.W., Pickett, S.D., Design principles for fragment libraries: maximizing the value of learnings from Pharma fragment-based drug discovery (FBDD) programs for use in academia. J Med Chem, 2016, 10.1021/acs.jmedchem.6b00197.
49. Kohlmann, A., Zech, S.G., Li, F., Zhou, T., Squillace, R.M., Commodore, L.,.. Dalgarno, D.C., Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J Med Chem 56 (2013), 1023–1040.
50. Korczynska, M., Le, D.D., Younger, N., Gregori-Puigjane, E., Tumber, A., Krojer, T.,.. Fujimori, D.G., Docking and linking of fragments to discover Jumonji histone demethylase inhibitors. J Med Chem 59 (2015), 1580–1598.
51. Krishnarjuna, B., Lim, S.S., Devine, S.M., Debono, C.O., Lam, R., Chandrashekaran, I.R.,.. Norton, R.S., Solution NMR characterization of apical membrane antigen-1 and small molecule interactions as a basis for designing new antimalarials. J Mol Recognit 29 (2016), 281–291.
52. Kulkarni, S.S., Hu, X., Doi, K., Wang, H.G., Manetsch, R., Screening of protein–protein interaction modulators via sulfo-click kinetic target-guided synthesis. ACS Chem Biol 6 (2011), 724–732.
53. Kwarcinski, F.E., Steffey, M.E., Fox, C.C., Soellner, M.B., Discovery of bivalent kinase inhibitors via enzyme-templated fragment elaboration. ACS Med Chem Lett 6 (2015), 898–901.
54. Lau, W.F., Withka, J.M., Hepworth, D., Magee, T.V., Du, Y.J., Bakken, G.A.,.. Mills, J.E., Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. J Comput Aided Mol Des 25 (2011), 621–636.
55. Leach, A.R., Hann, M.M., Burrows, J.N., Griffen, E.J., Fragment screening: an introduction. Mol Biosyst 2 (2006), 430–446.
56. Leung, E.W., Yagi, H., Harjani, J.R., Mulcair, M.D., Scanlon, M.J., Baell, J.B., Norton, R.S., (19) F NMR as a probe of ligand interactions with the iNOS binding site of SPRY domain-containing SOCS box protein 2. Chem Biol Drug Des 84 (2014), 616–625.
57. Lewis, W.G., Green, L.G., Grynszpan, F., Radic, Z., Carlier, P.R., Taylor, P.,.. Sharpless, K.B., Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed Engl 41 (2002), 1053–1057.
58. Lienard, B.M., Selevsek, N., Oldham, N.J., Schofield, C.J., Combined mass spectrometry and dynamic chemistry approach to identify metalloenzyme inhibitors. ChemMedChem 2 (2007), 175–179.
59. Linke, P., Amaning, K., Maschberger, M., Vallee, F., Steier, V., Baaske, P.,.. Rak, A., An automated microscale thermophoresis screening approach for fragment-based lead discovery. J Biomol Screen 21 (2016), 414–421.
60. Lodge, J.M., Rettenmaier, T.J., Wells, J.A., Pomerantz, W.C., Mapp, A.K., FP tethering: a screening technique to rapidly identify compounds that disrupt protein–protein interactions. Med Chem Commun 5 (2014), 370–375.
61. Ludlow, R.F., Verdonk, M.L., Saini, H.K., Tickle, I.J., Jhoti, H., Detection of secondary binding sites in proteins using fragment screening. Proc Natl Acad Sci U S A 112 (2015), 15910–15915.
62. Maurer, T., Garrenton, L.S., Oh, A., Pitts, K., Anderson, D.J., Skelton, N.J.,.. Fang, G., Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 109 (2012), 5299–5304.
63. Meiby, E., Simmonite, H., le Strat, L., Davis, B., Matassova, N., Moore, J.D.,.. Ohlson, S., Fragment screening by weak affinity chromatography: Comparison with established techniques for screening against HSP90. Anal Chem 85 (2013), 6756–6766.
64. Meyer, B., Peters, T., NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed 42 (2003), 864–890.
65. Mondal, M., Hirsch, A.K., Dynamic combinatorial chemistry: A tool to facilitate the identification of inhibitors for protein targets. Chem Soc Rev 44 (2015), 2455–2488.
66. Mondal, M., Groothuis, D.E., Hirsch, A.K.H., Fragment growing exploiting dynamic combinatorial chemistry of inhibitors of the aspartic protease endothiapepsin. Med Chem Commun 6 (2015), 1267–1271.
67. Mondal, M., Radeva, N., Koster, H., Park, A., Potamitis, C., Zervou, M.,.. Hirsch, A.K., Structure-based design of inhibitors of the aspartic protease endothiapepsin by exploiting dynamic combinatorial chemistry. Angew Chem Int Ed Engl 53 (2014), 3259–3263.
68. Monjas, L., Hirsch, A., Harnessing dynamic combinatorial chemistry in the search for new ligands for protein targets. Future Med Chem 7 (2015), 2095–2098.
69. Moumne, R., Catala, M., Larue, V., Micouin, L., Tisne, C., Fragment-based design of small RNA binders: Promising developments and contribution of NMR. Biochimie 94 (2012), 1607–1619.
70. Murray, C.W., Rees, D.C., Opportunity knocks: Organic chemistry for fragment-based drug discovery (FBDD). Angew Chem Int Ed Engl 55 (2016), 488–492.
71. Murray, C.W., Carr, M.G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S.,.. Woolford, A.J., Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem 53 (2010), 5942–5955.
72. Murray, C.W., Erlanson, D.A., Hopkins, A.L., Keseru, G.M., Leeson, P.D., Rees, D.C.,.. Richmond, N.J., Validity of ligand efficiency metrics. ACS Med Chem Lett 5 (2014), 616–618.
73. Murray, J.B., Roughley, S.D., Matassova, N., Brough, P.A., Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. J Med Chem 57 (2014), 2845–2850.
74. Navratilova, I., Hopkins, A.L., Fragment screening by surface plasmon resonance. ACS Med Chem Lett 1 (2010), 44–48.
75. Nonoo, R.H., Armstrong, A., Mann, D.J., Kinetic template-guided tethering of fragments. ChemMedChem 7 (2012), 2082–2086.
76. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A.,.. Rosenberg, S.H., An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005), 677–681.
77. Oster, L., Tapani, S., Xue, Y., Kack, H., Successful generation of structural information for fragment-based drug discovery. Drug Discov Today 20 (2015), 1104–1111.
78. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., Shokat, K.M., K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503 (2013), 548–551.
79. Oueis, E., Sabot, C., Renard, P.Y., New insights into the kinetic target-guided synthesis of protein ligands. Chem Commun (Camb) 51 (2015), 12158–12169.
80. Palmer, N., Peakman, T.M., Norton, D., Rees, D.C., Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD). Org Biomol Chem 14 (2016), 1599–1610.
81. Pearl, L.H., Prodromou, C., Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75 (2006), 271–294.
82. Reynolds, C.H., Protein–ligand cocrystal structures: We can do better. ACS Med Chem Lett 5 (2014), 727–729.
83. Roughley, S.D., Jordan, A.M., The medicinal chemist's toolbox: An analysis of reactions used in the pursuit of drug candidates. J Med Chem 54 (2011), 3451–3479.
84. Ruddigkeit, L., van Deursen, R., Blum, L.C., Reymond, J.L., Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J Chem Inf Model 52 (2012), 2864–2875.
85. Sadowsky, J.D., Burlingame, M.A., Wolan, D.W., McClendon, C.L., Jacobson, M.P., Wells, J.A., Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc Natl Acad Sci U S A 108 (2011), 6056–6061.
86. Scanlon, M.J., Norton, R.S., Fragment-based Drug Discovery, an Accessible Approach to New Therapeutics. Australian Biochemist, 44, 2013, 9–12.
87. Scheer, J.M., Romanowski, M.J., Wells, J.A., A common allosteric site and mechanism in caspases. Proc Natl Acad Sci U S A 103 (2006), 7595–7600.
88. Schiebel, J., Radeva, N., Koster, H., Metz, A., Krotzky, T., Kuhnert, M.,.. Klebe, G., One question, multiple answers: biochemical and biophysical screening methods retrieve deviating fragment hit lists. ChemMedChem 10 (2015), 1511–1521.
89. Schmidt, M.F., El-Dahshan, A., Keller, S., Rademann, J., Selective identification of cooperatively binding fragments in a high-throughput ligation assay enables development of a picomolar caspase-3 inhibitor. Angew Chem Int Ed Engl 48 (2009), 6346–6349.
90. Schmidt, M.F., Isidro-Llobet, A., Lisurek, M., El-Dahshan, A., Tan, J., Hilgenfeld, R., Rademann, J., Sensitized detection of inhibitory fragments and iterative development of non-peptidic protease inhibitors by dynamic ligation screening. Angew Chem Int Ed Engl 47 (2008), 3275–3278.
91. Schuffenhauer, A., Ruedisser, S., Marzinzik, A.L., Jahnke, W., Blommers, M., Selzer, P., Jacoby, E., Library design for fragment based screening. Curr Top Med Chem 5 (2005), 751–762.
92. Schulz, M.N., Landstrom, J., Bright, K., Hubbard, R.E., Design of a fragment library that maximally represents available chemical space. J Comput Aided Mol Des 25 (2011), 611–620.
93. Sharpless, K.B., Manetsch, R., In situ click chemistry: A powerful means for lead discovery. Expert Opin Drug Discovery 1 (2006), 525–538.
94. Shuker, S.B., Hajduk, P.J., Meadows, R.P., Fesik, S.W., Discovering high-affinity ligands for proteins: SAR by NMR. Science 274 (1996), 1531–1534.
95. Shultz, M.D., Improving the plausibility of success with inefficient metrics. ACS Med Chem Lett 5 (2014), 2–5.
96. Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J.,.. Elmore, S.W., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19 (2013), 202–208.
97. Surade, S., Ty, N., Hengrung, N., Lechartier, B., Cole, S.T., Abell, C., Blundell, T.L., A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR. Biochem J 458 (2014), 387–394.
98. Tsai, J., Lee, J.T., Wang, W., Zhang, J., Cho, H., Mamo, S.,.. Bollag, G., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105 (2008), 3041–3046.
99. Turner, D.M., Tom, C.T., Renslo, A.R., Simple plate-based, parallel synthesis of disulfide fragments using the CuAAC click reaction. ACS Comb Sci 16 (2014), 661–664.
100. Ward, R.A., Brassington, C., Breeze, A.L., Caputo, A., Critchlow, S., Davies, G.,.. Hudson, K., Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. J Med Chem 55 (2012), 3285–3306.
101. Warner, K.D., Homan, P., Weeks, K.M., Smith, A.G., Abell, C., Ferre-D'Amare, A.R., Validating fragment-based drug discovery for biological RNAs: Lead fragments bind and remodel the TPP riboswitch specifically. Chem Biol 21 (2014), 591–595.
102. Whiting, M., Muldoon, J., Lin, Y.C., Silverman, S.M., Lindstrom, W., Olson, A.J.,.. Fokin, V.V., Inhibitors of HIV-1 protease by using in situ click chemistry. Angew Chem Int Ed 45 (2006), 1435–1439.
103. Wielens, J., Headey, S.J., Deadman, J.J., Rhodes, D.I., Parker, M.W., Chalmers, D.K., Scanlon, M.J., Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1. ChemMedChem 6 (2011), 258–261.
104. Wielens, J., Headey, S.J., Rhodes, D.I., Mulder, R.J., Dolezal, O., Deadman, J.J.,.. Scanlon, M.J., Parallel screening of low molecular weight fragment libraries: Do differences in methodology affect hit identification?. J Biomol Screen 18 (2013), 147–159.
105. Wilfong, E.M., Du, Y., Toone, E.J., An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1. Bioorg Med Chem Lett 22 (2012), 6521–6524.
106. Willand, N., Desroses, M., Toto, P., Dirie, B., Lens, Z., Villeret, V.,.. Deprez, B., Exploring drug target flexibility using in situ click chemistry: Application to a mycobacterial transcriptional regulator. ACS Chem Biol 5 (2010), 1007–1013.
107. Wong, W., Bai, X.C., Brown, A., Fernandez, I.S., Hanssen, E., Condron, M.,.. Scheres, S.H., Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine. Elife, 3, 2014.
108. Woodhead, A.J., Angove, H., Carr, M.G., Chessari, G., Congreve, M., Coyle, J.E.,.. Woolford, A.J., Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 53 (2010), 5956–5969.
109. Yamane, J., Ohyabu, N., Yao, M., Takemoto, H., Tanaka, I., In-crystal chemical ligation for lead compound generation. J Appl Crystallogr 43 (2010), 1329–1337.
110. Yang, W., Fucini, R.V., Fahr, B.T., Randal, M., Lind, K.E., Lam, M.B.,.. Ballinger, M.D., Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. Biochemistry 48 (2009), 4488–4496.
111. Zhang, C., Ibrahim, P.N., Zhang, J., Burton, E.A., Habets, G., Zhang, Y.,.. Bollag, G., Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A 110 (2013), 5689–5694.